I-Mab (IMAB) Scheduled to Post Earnings on Thursday

I-Mab (NASDAQ:IMAB - Get Free Report) will be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

I-Mab (NASDAQ:IMAB - Get Free Report) last posted its earnings results on Wednesday, August 28th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

I-Mab Stock Down 0.9 %

Shares of NASDAQ IMAB traded down $0.01 during trading hours on Thursday, reaching $1.08. The stock had a trading volume of 387,877 shares, compared to its average volume of 350,549. The firm has a 50-day moving average of $1.20 and a 200-day moving average of $1.44. I-Mab has a fifty-two week low of $0.99 and a fifty-two week high of $2.54.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of I-Mab in a report on Tuesday, September 17th.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.